News Release

INDIANAPOLIS, Sept. 6, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Thursday, October 4, 2018 to discuss the company's presentations at the 54^th annual meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany. Remarks will focus primarily on data from the Phase 2b study of LY3298176, a GIP and GLP-1 dual receptor agonist. The webcast will begin at 7 p.m. Central European Time, or 1 p.m. Eastern Time.

Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/events.cfm. A replay will also be available on the website following the conference call.

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels.  F-LLY   

View original content with multimedia:http://www.prnewswire.com/news-releases/lilly-announces-webcast-to-discuss-easd-presentations-300707619.html

SOURCE Eli Lilly and Company